Investment Analysts’ Weekly Ratings Changes for Mentari Therapeutics (MTRI)

A number of research firms have changed their ratings and price targets for Mentari Therapeutics (NASDAQ: MTRI):

  • 11/13/2026 – Mentari Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $33.00 price target on the stock.
  • 11/11/2026 – Mentari Therapeutics is now covered by Zacks Research. They set a “hold” rating on the stock.
  • 11/11/2026 – Mentari Therapeutics is now covered by TD Cowen. They set a “strong-buy” rating on the stock.
  • 11/10/2026 – Mentari Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $30.00 price target on the stock.
  • 11/10/2026 – Mentari Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $30.00 price target on the stock.
  • 11/9/2026 – Mentari Therapeutics is now covered by Guggenheim. They set a “strong-buy” rating on the stock.

Mentari Therapeutics Price Performance

NASDAQ MTRI traded down $1.79 on Tuesday, reaching $18.07. The company had a trading volume of 156,386 shares, compared to its average volume of 79,503. Mentari Therapeutics has a 52-week low of $5.75 and a 52-week high of $23.30.

Insider Activity at Mentari Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc purchased 2,640 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were acquired at an average cost of $13.10 per share, for a total transaction of $34,584.00. Following the completion of the acquisition, the insider owned 98,297 shares in the company, valued at $1,287,690.70. This trade represents a 2.76% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.85% of the stock is currently owned by corporate insiders.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases.

Read More

Receive News & Ratings for Mentari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mentari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.